RecruitingPhase 1NCT07036029

NAL ER IPF Respiratory Function and Safety Study

An Open Label, In-Clinic Study to Assess Respiratory Function and Safety of Escalating Doses of Nalbuphine Extended-Release Tablets (NAL ER) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Sponsor

Trevi Therapeutics

Enrollment

10 participants

Start Date

Aug 21, 2025

Study Type

INTERVENTIONAL

Conditions

Idiopathic Pulmonary Fibrosis

Summary

The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Diagnosis of IPF as determined by a pulmonologist based on American Thoracic Society (ATS)/ European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) / Asociación Latinoamericana de Tórax (ALAT) guidelines.
SpO2 ≥ 92%, taken after at least 5 minutes in a sitting position, undisturbed and non-stimulated - Saturation of Hemoglobin with Oxygen as measured by pulse oximetry.
FVC ≥ 40% of Global Lung Function Initiative (GLI) 2012 predicted values- Forced Vital Capacity, as determined by spirometry adhering to ATS/ERS guidelines.

Exclusion Criteria7

Exacerbation of IPF in the last 3 months.
Positive results for coronavirus infection (COVID-19) at Day -2, prior to Admission to the clinical research unit (CRU).
Diagnosis of Chronic Obstructive Pulmonary Disease (COPD), or an forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <0.8.
Currently using any overnight oxygen therapy at any level or delivered by any modality. Intermittent daytime oxygen use of any duration is allowed.
Diagnosis of sleep disordered breathing (e.g., sleep apnea).
Upper or lower respiratory tract infection within the 8 weeks prior to admission to the CRU.
Clinical history of aspiration pneumonitis.